Format

Send to

Choose Destination
Clin Genitourin Cancer. 2009 Oct;7(3):E90-2. doi: 10.3816/CGC.2009.n.030.

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.

Author information

1
Dana-Farber Cancer Institute, Boston, MA, USA. osartor@tulane.edu

Abstract

BACKGROUND:

Ketoconazole is a commonly used secondary hormonal therapy in castration-refractory prostate cancer (CRPC), but disease progression inevitably occurs. Both prostatic and metastatic lesions in patients with CRPC overexpress 5-alpha reductase (SRDA5) type I. We hypothesized that SRDA5 inhibition in combination with ketoconazole would mitigate progression after treatment with ketoconazole alone.

PATIENTS AND METHODS:

A total of 10 patients with CRPC with progression after ketoconazole treatment were treated with a combination of ketoconazole plus dutasteride 0.5 mg/day, a dual SRDA5 inhibitor.

RESULTS:

After dutasteride addition, 8 (80%) of the 10 patients had varying degrees of prostate-specific antigen (PSA) decline relative to baseline. Median progression-free survival after dutasteride addition was 4.9 months (range, 2.7+ to 9.8 months); no patient had a >OR= 50% PSA decline.

CONCLUSION:

We conclude that dutasteride added to ketoconazole at the time progression might prolong time to PSA progression in patients with CRPC.

PMID:
19815488
DOI:
10.3816/CGC.2009.n.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center